doi: 10.1186/s12933-022-01474-z Summary Keywords glucagon-like peptide-1, glucagon-like peptide-1 receptor agonist, cardiovascular diseases, major adverse cardiovascular events, diabetes mellitus Citation Ferhatbegovi L, Mri D and Maci-Dankovi A (2023) The benefits of GLP1 receptors in cardiovascular diseases
Wegovy is also licensed to help reduce cardiovascular risk, and it doesnt interact with the oral contraceptive pill, both of which may be relevant depending on your health and circumstances
When you might need a maintenance dose or another medication Before deciding what comes next, it helps to understand the tools available after tapering off tirzepatide
Semaglutide has been approved for use in managing type 2 diabetes (as in Ozempic), and it is available for weight loss in other forms (such as Wegovy)
Unlike traditional single-pathway or dual-pathway incretin compounds, this molecule is structurally designed to activate GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors simultaneously